SCHEMBL20744401

SCHEMBL20744401

COCc1cccc2nsnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
HSD17B10 Q99714 3/20 0.47
MAPT P10636 2/20 0.47
HIF1A Q16665 1/20 0.47
ALDH1A1 P00352 5/20 0.43
HPGD P15428 4/20 0.43
CASP1 P29466 2/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
EPHA2 P29317 1/20 0.42
KDR P35968 1/20 0.42
EPHB4 P54760 1/20 0.42
POLB P06746 1/20 0.41
TXNRD1 Q16881 1/20 0.41
TXNRD3 Q86VQ6 1/20 0.41
TXNRD2 Q9NNW7 1/20 0.41
TSHR P16473 2/20 0.40
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL762893 0.79 KMT2A (0.56) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL14075103 0.78 KDM4E (0.43) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL12844407 0.76 MAPT (0.48) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL7718402 0.76 KDM4E (0.52) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL4678156 0.76 KDM4E (0.52) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL25399698 0.76 MAPT (0.57) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL2805013 0.76 KDM4E (0.52) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL12775851 0.75 KDM4E (0.47) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL13197096 0.75 KDM4E (0.47) KDM4EHSD17B10MAPTHIF1AALDH1A1
SCHEMBL13940123 0.75 ALDH1A1 (0.49) KDM4EHSD17B10MAPTHIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111344281-B Potassium channel inhibitors substituted benzimidazoles 阿塞西翁制药公司 2023-11-14 CN disclosed
US-20200216398-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-07-09 US disclosed
US-20200216398-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-07-09 US disclosed
CN-111344281-A Potassium channel inhibitors of substituted benzimidazoles 阿塞西翁制药公司 2020-06-26 CN disclosed
EP-3668841-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2020-06-24 EP disclosed
WO-2019034603-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2019-02-21 WO disclosed
WO-2019034603-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216398-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN1, KCNN2, KCNJ2 KDM4E 1332/4885HSD17B10 1306/4885MAPT 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.